Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia.
Tuğba ÇetintepeFüsun GedizIşın AkyarLutfi ÇetintepeAli Murat KoçPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
PML is a rare and often fatal demyelinating disease of the central nervous system (CNS) that is exclusively seen in immunocompromised patients and there is no specific agent to treat PML. The case discussed here, highlights that the use of ibrutinib in chronic lymphocytic leukemia (CLL) therapy may result in PML.
Keyphrases
- chronic lymphocytic leukemia
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- multiple sclerosis
- prognostic factors
- peritoneal dialysis
- blood brain barrier
- stem cells
- mesenchymal stem cells
- patient reported outcomes
- combination therapy
- cerebrospinal fluid
- acute respiratory distress syndrome